Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will be delivering a corporate overview at the 2016 Aegis Growth Conference taking place September 20-22, 2016 in Las Vegas and at the Ladenburg Thalmann 2016 Healthcare Conference taking place on September 27, 2016 in New York City. 2016 Aegis Growth Conference Date and Time: September 21, 2016, 10:45 AM PDT Website: 2016 Aegis Growth Conference Format: Company Presentation Presenter: Kenneth A. Berlin Ladenburg Thalmann 2016 Healthcare Conference Date and Time: September 27, 2016, 8:30 AM EDT Website: Ladenburg Thalmann 2016 Healthcare Conference Format: Company Presentation Presenter: Kenneth A. Berlin Both of Mr. Berlin's presentations will be webcast live on the internet and can be accessed by visiting the Investor Relations section on the Company's website at www.rosettagx.com. A replay of the webcasts will be archived on the Rosetta Genomics website for 90 days following the presentation. About Rosetta Genomics Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company now offers core FISH, IHC and PCR-based testing capabilities and partnerships in Pathology, Oncology and Urology that provide additional content and platforms that complement Rosetta's microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company's Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. For more information visit www.rosettagx.com. Forward-Looking Statement Disclaimer Various statements in this release concerning Rosetta's future expectations, plans and prospects including management presenting at certain conferences constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.